Saturday Edition
Stay updated with Archyde – your source for breaking news, global headlines, economy, entertainment, health, technology, and sports. Fresh stories daily.
Published in Nature Medicine in September 2026, a phase 1 clinical trial evaluating the oral, dual on-off binding KRAS G12D inhibitor GFH375 demonstrates encouraging response rates in patients with non-small ... Read More
Continuous Coverage
San Jose, California, often gets boxed into its identity as the beating heart of Silicon Valley, but looking…
Spotify Wrapped 2026 is finally solving its most notorious data-skewing problem by introducing a profile toggle that filters…
As the winter respiratory virus season approaches, leading US physicians recommend that everyone aged 6 months and older…
JustWatch, the streaming guide used by millions to locate movies and television shows, is launching its own platform…
These limited engagement packages provide fans with rare direct access, photo opportunities, and premium seating tiers. Fantasy &…
Choosing the right device means dissecting exact screen panels, refresh-rate taxes, and hardware pricing tiers. The Paperwhite Engineering…
Global Affairs
Earlier this week, the Saudi Arabian government announced the discovery of approximately 110 Juta Ton rare earth minerals…
Markets And Money
As the sports season kicks off, the surge in demand for live match broadcasts has triggered a parallel…
Digital Culture
On Thursday, September 10, NASA and IBM publicly released an open-source foundational AI model designed to analyze decades…
Science And Wellbeing
Bexobrutideg has demonstrated high clinical response rates across multiple treatment lines in patients with chronic lymphocytic leukemia and…
Screen And Sound
Croxteth Country Park in Liverpool is set to become the first site to benefit from the Queen Elizabeth…
Fixtures And Form
Defending champion Busan KCC has secured a commercial partnership, becoming the official title sponsor for the 2026–2027 KBL…
